NEUROTROPE BIOSCIENCE, INC. | Business Contracts

First Amendment to the Securities Purchase Agreement dated as of May 11, 2023 by and among Synaptogenix, Inc. and certain investors party thereto (Filed With SEC on May 15, 2023)

Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on May 15, 2023)

Engagement Letter, dated November 17, 2022 by and between Synaptogenix, Inc. and Katalyst Securities LLC (Filed With SEC on November 18, 2022)

Form of Registration Rights Agreement (Filed With SEC on November 18, 2022)

Form of Purchase Agreement (Filed With SEC on November 18, 2022)

Form of Warrant (Filed With SEC on November 18, 2022)

Amendment to the Synaptogenix, Inc. 2020 Equity Incentive Plan (Filed With SEC on October 13, 2022)

Amendment to the offer letter, dated August 4, 2022, by and between the Company and Alan J. Tuchman, M.D (Filed With SEC on August 5, 2022)

Master Services Agreement, between Synaptogenix, Inc. and Worldwide Clinical Trials, Inc., dated as of February 7, 2022 and Work Order, dated May 12, 2022 (Filed With SEC on August 5, 2022)

Securities Purchase Agreement, dated June 14, 2021, by and among Synaptogenix, Inc. and the Buyers signatory thereto (Filed With SEC on June 16, 2021)

Form of Series G Warrant (Filed With SEC on June 16, 2021)

Form of Pre-Funded Warrant (Filed With SEC on June 16, 2021)

Form of Broker Warrant (Filed With SEC on June 16, 2021)

Registration Rights Agreement, dated June 14, 2021, by and among Synaptogenix, Inc. and the Buyers signatory thereto (Filed With SEC on June 16, 2021)

Engagement Letter, dated June 14, 2021, by and between Synaptogenix, Inc. and Katalyst Securities LLC (Filed With SEC on June 16, 2021)

Amendment to the Synaptogenix, Inc. 2020 Equity Incentive Plan (Filed With SEC on April 8, 2021)

Amended and Restated Technology License and Services Agreement among Neurotrope BioScience, Inc., Blanchette Rockefeller Neurosciences Institute and NRV II, LLC, made as of... (Filed With SEC on March 30, 2021)

Second Amendment to the Amended and Restated Technology License by and between Neurotrope BioScience, Inc. and Cognitive Research Enterprises, Inc., dated November 29, 2018 (Filed With SEC on March 30, 2021)

Services Agreement by and between Neurotrope, Inc. and Worldwide Clinical Trials, Inc., dated as of May 4, 2018 (assumed by Synaptogenix, Inc. on December 7, 2020) (Filed With SEC on March 30, 2021)

Statement of Work Agreement between Neurotrope BioScience, Inc. and Blanchette Rockefeller Neurosciences Institute, dated November 12, 2015 (Filed With SEC on March 30, 2021)

Letter Agreement between the Neurotrope, Inc. and Neurosciences Research Ventures, Inc. regarding NRV Director Nominees, dated November 12, 2015 (assumed by Synaptogenix, Inc. on... (Filed With SEC on March 30, 2021)

Amendment to Amended and Restated Technology License and Services Agreement among Neurotrope BioScience, Inc., Blanchette Rockefeller Neurosciences Institute and NRV II, LLC,... (Filed With SEC on March 30, 2021)

Services Agreement between Neurotrope BioScience, Inc. and Worldwide Clinical Trials, Inc., dated October 9, 2015 (Filed With SEC on March 30, 2021)

Statement of Work Agreement dated February 4, 2015, and effective as of October 1, 2014, between Neurotrope Bioscience, Inc. and BRNI (Filed With SEC on March 30, 2021)

Form of Director Indemnification Agreement (Filed With SEC on March 30, 2021)

Nonemployee Director Compensation Policy (Filed With SEC on March 30, 2021)

Employment Agreement, dated as of October 1, 2013, between Neurotrope, Inc., and Robert Weinstein (assumed by Synaptogenix, Inc. on December 7, 2020) (Filed With SEC on March 30, 2021)

Placement Agency Agreement, dated January 21, 2021, by and between Synaptogenix, Inc., and GP Nurmenkari Inc (Filed With SEC on January 22, 2021)

Engagement Letter, dated January 20, 2021, by and between Synaptogenix, Inc. and Katalyst Securities LLC (Filed With SEC on January 22, 2021)

Registration Rights Agreement, dated January 21, 2021, by and among Synaptogenix, Inc. and the Buyers signatory thereto (Filed With SEC on January 22, 2021)

Securities Purchase Agreement, dated January 21, 2021, by and among Synaptogenix, Inc. and the Buyers signatory thereto (Filed With SEC on January 22, 2021)

Form of Broker Warrant (Filed With SEC on January 22, 2021)

Form of Pre-Funded Warrant (Filed With SEC on January 22, 2021)

Form of Series F Warrant (Filed With SEC on January 22, 2021)

Form of Series E Warrant (Filed With SEC on January 22, 2021)

Rights Agreement, dated as of January 19, 2021, between Synaptogenix, Inc. and Philadelphia Stock Transfer, Inc., as rights agent (Filed With SEC on January 19, 2021)

Form of Stock Option Agreement under 2020 Equity Incentive Plan of Synaptogenix, Inc (Filed With SEC on December 10, 2020)

2020 Equity Incentive Plan of Synaptogenix, Inc (Filed With SEC on December 10, 2020)

Offer Letter, dated as of December 7, 2020, by and between Synaptogenix, Inc. and Alan J. Tuchman, Ph.D (Filed With SEC on December 10, 2020)

Separation Agreement, dated as of December 1, 2020, by and between Charles S. Ryan, J.D., Ph.D. and Synaptogenix, Inc (Filed With SEC on December 10, 2020)

Tax Matters Agreement, dated as of December 6, 2020, by and between Neurotrope, Inc. and Synaptogenix, Inc (Filed With SEC on December 10, 2020)

Separation and Distribution Agreement, dated as of December 6, 2020, by and between Neurotrope, Inc. and Synaptogenix, Inc (Filed With SEC on December 10, 2020)

Form of Tax Matters Agreement by and between Neurotrope, Inc. and Neurotrope Bioscience, Inc (Filed With SEC on October 30, 2020)

Form of Separation and Distribution Agreement by and between Neurotrope, Inc. and Neurotrope Bioscience, Inc (Filed With SEC on October 30, 2020)

Form of Stock Option Agreement under 2020 Equity Incentive Plan (Filed With SEC on October 30, 2020)

Form of 2020 Equity Incentive Plan (Filed With SEC on October 30, 2020)

Specimen Common Stock Certificate (Filed With SEC on October 30, 2020)

Services Agreement between Neurotrope BioScience, Inc. and Worldwide Clinical Trials, Inc., dated July 23, 2020 (Filed With SEC on October 9, 2020)

NEUROTROPE BIOSCIENCE, INC. (48)